<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cold Spring Harb Perspect Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Cold Spring Harb Perspect Med</journal-id>
<journal-id journal-id-type="publisher-id">cshperspectmed</journal-id>
<journal-id journal-id-type="hwp">cshperspectmed</journal-id>
<journal-title-group>
<journal-title>Cold Spring Harbor Perspectives in Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2157-1422</issn>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
<publisher-loc>Cold Spring Harbor, New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28213432</article-id>
<article-id pub-id-type="pmc">5495050</article-id>
<article-id pub-id-type="doi">10.1101/cshperspect.a026674</article-id>
<article-id pub-id-type="publisher-id">a026674</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>116</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Perspectives</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting Cancer Cells with BET Bromodomain Inhibitors</article-title>
<alt-title alt-title-type="left-running">Y. Xu and C.R. Vakoc</alt-title>
<alt-title alt-title-type="right-running">BET Inhibition in Cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Yali</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vakoc</surname>
<given-names>Christopher R.</given-names>
</name>
</contrib>
</contrib-group>
<aff>Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724</aff>
<author-notes>
<corresp>
<italic>Correspondence:</italic>
<email>vakoc@cshl.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>7</month>
<year>2017</year>
</pub-date>
<volume>7</volume>
<issue>7</issue>
<elocation-id>a026674</elocation-id>
<permissions>
<copyright-statement>
<ext-link ext-link-type="uri" xlink:href="http://www.perspectivesinmedicine.org/site/misc/terms.xhtml">Copyright Â© 2017 Cold Spring Harbor Laboratory Press; all rights reserved</ext-link>
</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="cshperspectmed-CCH-a026674.pdf"></self-uri>
<abstract>
<p>Cancer cells are often hypersensitive to the targeting of transcriptional regulators, which may reflect the deregulated gene expression programs that underlie malignant transformation. One of the most prominent transcriptional vulnerabilities in human cancer to emerge in recent years is the bromodomain and extraterminal (BET) family of proteins, which are coactivators that link acetylated transcription factors and histones to the activation of RNA polymerase II. Despite unclear mechanisms underlying the gene specificity of BET protein function, small molecules targeting these regulators preferentially suppress the transcription of cancer-promoting genes. As a consequence, BET inhibitors elicit anticancer activity in numerous malignant contexts at doses that can be tolerated by normal tissues, a finding supported by animal studies and by phase I clinical trials in human cancer patients. In this review, we will discuss the remarkable, and often perplexing, therapeutic effects of BET bromodomain inhibition in cancer.</p>
</abstract>
<abstract abstract-type="precis">
<p>Small molecules that target BET proteins preferentially suppress transcription of cancer-promoting genes and induce anticancer responses in vivo. The mechanisms that underlie this gene specificity are just beginning to be revealed.</p>
</abstract>
<counts>
<page-count count="17"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>